Effects of a next-generation neurotrophic compound in a toxin model of Parkinson’s disease
Objective: Investigate the effects of a peripherally administered novel neurotrophic compound, CMx01a, in 6-hydroxydopamine rat model of Parkinson’s disease. Background: Neurotrophic factors are promising drug…Creating National Competencies in Physical Activity for Exercise Professionals Working with People with Parkinson’s Disease
Objective: On March 5-6th 2020, the Parkinson’s Foundation is convening a meeting to assemble thought leaders in physical activity and education for Parkinson’s disease. Our…Thiazolidinedione use is associated with reduced risk of Parkinson’s disease in patients with diabetes
Objective: This meta-analysis is aimed to explore the association between thiazolidinedione (TZD) use and Parkinson’s disease (PD) risk. Background: Recent epidemiological studies found protective effects of TZD class of drugs in…Reduced Striatal VMAT2 in REM Sleep Behavior Disorder: A Gateway to Preclinical Parkinson’s Disease
Objective: To determine the degree of striatal degeneration that occurs in subjects with REM Sleep Behavior Disorder (RBD) and assess whether this is an appropriate…Phase I-II first-in-human clinical trial of intraputamenal CDNF in Parkinson’s disease: Topline results of the six-month double-blind placebo-controlled main study and the six-month active treatment extension study
Objective: To assess the safety and tolerability and to explore the preliminary efficacy of intermittent intraputamenal monthly infusions of CDNF in subjects with advanced idiopathic…Phase I-II first-in-human clinical trial of intraputamenal CDNF in Parkinson’s disease: Exploratory fluid-based biomarker endpoints of the 12-month treatment period
Objective: To explore fluid-based biomarkers in subjects with advanced idiopathic Parkinson’s disease (PD) before and after intermittent intraputamenal monthly infusions of CDNF. Background: CDNF is…Phase I-II first-in-human clinical study of intraputamenal CDNF in Parkinson’s disease: Exploratory PET imaging endpoints of the 12-month treatment period
Objective: To test if intermittent intraputamenal monthly infusions of CDNF have an effect on striatal dopamine transporter (DAT) binding, as measured by PET, in subjects…Yerba mate tea (Ilex paraguariensis) exerts a neuroprotective effect on intrastriatal 6-OHDA-lesioned mice model of Parkinson’s disease
Objective: We set to investigate the possible neuroprotective effect of yerba mate (YM) consumption on dopaminergic neurons in a mice model of Parkinson’s disease (PD). Background: The motor…Ferroptosis, a recently identified cell death, as a therapeutic target for Parkinson’s disease.
Objective: We aim to determine in a cell model neuroprotective effects of targeting lipoxygenases (LOXs), central players in Ferroptosis, a novel regulated iron-dependent cell death…Development of Mucoadhesive Sustained Release Floating Tablets of Silymarin using Natural Polymer for Improved Anti-Parkinson Efficacy
Objective: The objective of the present investigation was to develop Mucoadhesive sustained release floating tablets of Silymarin using natural polymers (Coccinia grandis and Rumex vasicarious)…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 15
- Next Page »